Search results
Results from the WOW.Com Content Network
Secondary polycythemia is the most common cause of polycythemia. It occurs in reaction to chronically low oxygen levels , medications, other genetic mutations that impact the body's ability to transport or detect oxygen, or, rarely because of certain cancers.
Basophilia, as it is primarily a secondary condition, is treated by addressing the causative disease or disorder. The underlying condition will determine what treatment is appropriate. Specifically in cases of allergic reactions or associated with chronic inflammation, treating the underlying cause is critical to avoid further, potentially ...
In oncology, polycythemia vera (PV) is an uncommon myeloproliferative neoplasm in which the bone marrow makes too many red blood cells. [1] The majority of cases [2] are caused by mutations in the JAK2 gene, most commonly resulting in a single amino acid change in its protein product from valine to phenylalanine at position 617.
The US Food and Drug Administration has launched an investigation into certain treatments for cancer and whether these therapies themselves may be associated with the risk of developing secondary ...
Symptomatic features of paraneoplastic syndrome cultivate in four ways: endocrine, neurological, mucocutaneous, and hematological.The most common presentation is a fever (release of endogenous pyrogens often related to lymphokines or tissue pyrogens), but the overall picture will often include several clinical cases observed which may specifically simulate more common benign conditions.
The cause for the disorder is related to a genetic mutation of the HBB gene. This gene is responsible for providing the instructions to produce beta-globin; one of the major components of hemoglobin. The two classification types of beta thalassemia are thalassemia major (also known as Cooley's anemia) and thalassemia intermedia.
Treatment of patients with this POEMS syndrome variant who have evidence of bone lesions and/or myeloma proteins are the same as those for POEMS syndrome patients. In the absence of these features, treatment with rituximab , a monoclonal antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab , a monoclonal ...
Erythrocytosis (increase in the number of red blood cells) Leukocytosis (increase in the number of white blood cells) Thrombocytosis (increase in the number of platelets) Myeloproliferative disorder; Transient myeloproliferative disease; Coagulopathies (disorders of bleeding and coagulation) Thrombocytosis; Recurrent thrombosis